Hoth Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Hoth Therapeutics with a Buy rating and $4 price target. Hoth is a clinical-stage biopharmaceutical company developing novel medicines for unmet medical needs, the analyst tells investors in a research note. The firm says Hoth possesses a broad portfolio of earlier-stage assets, which it conservatively does not include in its valuation assessment. It believes HT-001 represents a risk-mitigated clinical-stage program.